AutoGenomics gives IPO another go with $65M offering

Diagnostics company AutoGenomics is again trying its hand at going public, filing for a $65 million IPO and planning to trade under AGMX.

As Xconomy notes, AutoGenomics filed for an $86.3 million IPO back in 2008, but withdrew the offering in 2011. The company offers a suite of assays and diagnostic platforms, including its FDA-cleared Infiniti gene analyzer. In its filing with the SEC, AutoGenomics says it plans to put the prospective $65 million toward expanding its sales force and building up its marketing operation.

AutoGenomics reported $13 million in sales in the last fiscal year, and the company pulled in a $459,000 net profit on $8.7 million in revenue in the first 6 months of 2012, Xconomy reports.

The company offers about 50 tests for Infinity, including applications in personalized medicine, oncology and infectious disease. It has 15 tests under development, Xconomy notes, including assays for HPV and mutations in the cancer-related BRAF gene.

- here's AugoGenomics' filing
- read the Xconomy story

Suggested Articles

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.